OaCP IE LTD is an innovative biotechnology company that is revolutionizing oncology diagnostics by dramatically accelerating DNA and genetic test turnaround times. Our patented, IVDR-certified reagent platforms compress In Situ Hybridization (FISH) test durations from days to just 2 hours—reducing laboratory operational costs by up to 50% without requiring hardware modifications, new equipment, or protocol redesign.
The Problem We Solve
Standard genetic hybridization tests in cancer care take 2 to 3 working days to deliver results. Every week of treatment delay increases a patient’s mortality risk by up to 10%, creating a critical bottleneck in clinical decision-making and generating billions in avoidable healthcare costs.
Our Solution & Core Technology
Accelerated Chemistry (RAPID-ISH / SMART-ISH): Proprietary, safe catalysts added directly to existing FISH probes, reducing hybridization time to 40 minutes (total test time: 2 hours) while maintaining over 98% diagnostic accuracy. 100% hardware-agnostic with zero switching costs.
AI Diagnostic Co-Pilot (AICP): An AI-powered suite trained on over 30,000+ pathology cases that provides real-time quality control and automated artifact detection in under 30 seconds, standardizing diagnostic quality across laboratories.
Intellectual Property & Regulatory Approval
Global IP Moat: Granted patents covering our core buffer technology in the European Union, the USA, China, and India.
Certifications: Full CE-IVD / IVDR compliance and ISO 13485 certification, enabling immediate commercial deployment in clinical oncology, veterinary pathology, and microbiology.
Global Traction & Commercial Alliances
Commercial Partnerships: Active collaborations and supplier agreements with global diagnostic and microscopy leaders, including Roche, Olympus/Evident, and Ikonisys.
International Reach: Established sales and distribution networks across Europe (Italy, Spain), Asia (Japan, KSA), and key pilot sites in the US (University of Michigan).
Institutional Validation: Supported by leading venture funds and accelerators, including SOSV, Bio4Dreams, and the Ministry of Investment of Saudi Arabia (MISA).
Why We Are Participating in Belt Road Summit 2026
We are actively seeking strategic partnerships to scale our footprint across Asia, the Middle East, and the broader EMEA region. We are looking to engage with:
Regional Distributors & Hospital Networks: To expand distribution of our IVDR-approved diagnostic reagents.
OEM & Microscope Manufacturers: To integrate our AICP AI quality-control software into automated pathology platforms.
Institutional & Strategic Investors: To participate in our current growth financing round ($2.7M) to fund international regulatory expansion (FDA 510(k), SFDA) and market scale-up.
Seeking VC & healthcare partners.
OaCP is raising a $2.7M Pre-Series A round to scale its IVDR-approved cancer diagnostic tech. Patented reagents cut test times from days to 2h, saving 50% lab costs. IP in EU/US/CN/IN, Roche partner.